Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262846 · ClinicalTrials.gov registry record · Phase 4
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
A Phase 4 study of HIV Infection, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT01262846 is a Phase 4 study of HIV Infection that has completed, run by University of Pennsylvania. The registered enrollment target is 195 participants, below the 240-participant average among 73 other HIV Infection trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01262846, a Phase 4 study of HIV Infection, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals. Our hypothesis is that Fluzone® HD will be safe and more immunogenic than the currently used vaccine
Conditions Studied
Interventions
- BIOLOGICAL Fluzone®
Study Locations (1)
Pennsylvania
- Clinical Trials Unit. University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262846
The ClinicalTrials.gov registry entry for NCT01262846 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 73 other HIV Infection trials with a reported enrollment target (19% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which Fluzone® is the first listed.
NCT01262846 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01262846 about?
NCT01262846 is a clinical study titled "Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals". The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals. Our hypothesis is that Fluzone® HD will be safe and more immunogenic than the currently used vaccine
What is the current status of trial NCT01262846?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 195 participants. The study started on 2010-11. Estimated completion is 2011-04.
What conditions does trial NCT01262846 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT01262846?
The interventions under investigation include: Fluzone® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01262846?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01262846 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
COMPLETED · Phase 4
-
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
COMPLETED · Phase 4
-
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
COMPLETED · Phase 4
-
Safety and Efficacy Study of Switching From Epzicom to Truvada
COMPLETED · Phase 4
-
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.